Hostname: page-component-586b7cd67f-t8hqh Total loading time: 0 Render date: 2024-11-23T01:05:56.545Z Has data issue: false hasContentIssue false
  • English
  • Français

P0321 - Changes in quality of life in ADHD-patients treated with extended-release Methylphenidate (OROS®-MPH) - results from an open-label naturalistic study

Published online by Cambridge University Press:  16 April 2020

C. Mitt ,
W. Arend ,
B. Schauble ,
L. Hargarter  and
F. Mattejat
C. Mitt
Affiliation:
Private Practice, Solingen, Germany
W. Arend
Affiliation:
Private Practice, Kassel, Germany
B. Schauble
Affiliation:
Medical & Scientific Affairs, Janssen-Cilag, Neuss, Germany
L. Hargarter
Affiliation:
Medical & Scientific Affairs, Janssen-Cilag, Neuss, Germany
F. Mattejat
Affiliation:
Department of Child and Adolescent Psychiatry, University of Marburg, Marburg, Germany

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Objectives:

To explore changes in daily functioning (C-GAS) and quality of life (ILC) in children and adolescents with ADHD OROS®-MPH and their parents.

Methods:

Full analysis. Open label non-interventional trial in children & adolescents with ADHD (ICD-10 criteria) treated with flexible dose OROS MPH for 3 months (42603-ATT-4001). Effectiveness parameter were C-GAS, ILC adolescents and parents and IOWA Conners' parent rating scale at baseline and endpoint.

Results:

598 patients with ADHD (ICD-10 criteria; Ø age 10.4 years ± 2.6; 84.8% male) were documented. 81.6% completed the observation. Mean OROS MPH dose at last observation was 33.5 mg/day (SD ± 13.3). Patients improved on C-GAS from 58.9±14.7 to 71.2±15.1 (p<0.001). IOWA Connors Symptoms decreased from 29.0 ± 10.5 to 18.5 ± 10.6 (p<0.0001). ILC improved from 18.8 ± 4.0 to 20.8±3.8 in children and adolescents (p<0.0001) and from 17.2±3.9 to 19.7±3.9 in parents (p<0.001). At endpoint, 76.8% of patients showed at least minimal improvement on CGI-C. Adverse events were reported in 28.8% of patients. AEs listed in ≥2% of patients were insomnia (7.7%), anorexia (3.9%), ineffectiveness (2.8%), headache (2.3%), nervousness (2.2%) and involuntary muscle contractions (2.2%). There were no significant changes in blood pressure or pulse.

Conclusion:

Treatment with OROS®-MPH was associated with a clinically relevant improvement in daily functioning in patients with ADHD and Qol improved significantly in patients and their parents. Treatment with OROS®-MPH was well tolerated.

Type
Poster Session III: Miscellaneous
Information
European Psychiatry , Volume 23 , Issue S2: 16th AEP Congress - Abstract book - 16th AEP Congress , April 2008 , pp. S394
Copyright
Copyright © European Psychiatric Association 2008
Submit a response

Comments

No Comments have been published for this article.